🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the USA / NCT04339699
Recruiting Not applicable

NobleStitch EL STITCH Trial is a PFO Comparative Trial

NCT04339699 · tracked via the Priya Life Science USA tracker
Sponsor
Nobles Medical Technologies II Inc
Phase
Not applicable
Started
2021-01-01
Last updated
2026-03-23

Condition(s) studied

Foramen Ovale, PatentStroke, Ischemic

Investigational drug(s) / intervention(s)

NobleStitch™EL Suture Mediated Closure SystemAmplatzer PFO Occluder

NobleStitch™EL Suture Mediated Closure System: Percutaneous closure of Patent Foramen Ovale (PFO) using NobleStitch™EL suture Medicate Closure System

Amplatzer PFO Occluder: Percutaneous closure of Patent Foramen Ovale (PFO) using Amplatzer PFO Occluder

Study summary

STITCH - Prospective Multi-Center Comparative Parallel Concurrent Study of the NobleStitch™ EL versus FDA-approved Amplatzer Occluder device for closure of Patent Foramen Ovale to prevent recurrent Ischemic stroke.

Eligibility

Sex
ALL
Min age
18 Years
Max age
60 Years
Healthy volunteers
No
Inclusion Criteria: * Provision of signed and dated informed consent form * Stated willingness to comply with all study procedures and availability for the duration of the study * Male or female ages 18 - 60 years old * A PFO and a Cryptogenic Stroke verified by a neurologist * Stroke is defined as an acute focal neurological deficit, presumed to be due to focal ischemia, and either: * Symptoms persisting ≥24 hours, or * Symptoms persisting \<24 hours with Magnetic Resonance or CT findings of a new, neuroanatomical relevant infarct * Cryptogenic stroke was defined as a stroke of unknown cause * Prolonged cardiac rhythm monitoring (recommended 30 days and not less than 24 hours required) * Intra and extracranial artery imaging: Magnetic Resonance Angiography, CT angiography, or contrast angiography, or contrast angiography or echocardiography of the carotid arteries to rule out ischemic stroke associated with atherosclerotic plaque, arterial dissection, or other vascular diseases. (The aortic arch may also be evaluated by TEE). * Hypercoagulable state assessment to rule out an underlying hypercoagulable state Exclusion Criteria: * Female participant who is pregnant, lactating or planning a pregnancy during the course of the study * Age \<18 or \> 60 years of age * Previous myocardial infarction or unstable angina within 6 months * Clinically significant mitral or aortic valve stenosis or severe regurgitation * Left Ventricular Ejection Fraction \<50 percent * Progressive neurological dysfunction or reduced life expectancy * Contrast allergy * Atrial Septal Defect (baseline left to right shunt assessed by TEE or other congenital heart diseases * Active Endocarditis * Perspective participants with known causes of Ischemic Stroke * Arterial dissection * Contraindicated or unsuitable for antiplatelet agents or oral anticoagulants * Perspective participants with prosthetic heart valves * Uncontrolled diabetes Mellitus * Pulmonary hypertension * Uncontrolled systemic hypertension * Intracranial pathology * Neurological deficits not due to stroke that may affect neurologic assessments * Active autoimmune disease * Active infection * Alcohol and/or drug abuse * A requirement for chronic anticoagulation therapy that cannot be discontinued * Anatomic features (inability to achieve vascular access)

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
TMC HealthCare Tucson Arizona Recruiting
Ospedale S. Eugenio Rome Lazio Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04339699 on ClinicalTrials.gov ↗ ← All trials in the USA